Advanced Lung Cancer Inflammation Index for Predicting Prognostic Risk for Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Abstract

Purpose The decreased advanced lung cancer inflammation index (ALI), defined as body mass index (BMI) * albumin (Alb)/neutrophil-to-lymphocyte ratio (NLR), is an independent prognostic risk factor for overall survival in gastric, lung, and colorectal cancers. This study aimed to investigate the value of ALI in predicting the risk of major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS). Patients and Methods A total of 1624 patients with ACS undergoing percutaneous coronary intervention (PCI) were consecutively enrolled between January 2016 and December 2018. Follow-up data were collected at 1, 3, 6, and 12 months and annually thereafter. The primary endpoints were MACEs. All endpoints were defined as all-cause mortality, recurrent angina pectoris, restenosis/intra stent thrombosis, stroke, heart failure, and all-cause bleeding. Results The MACEs group and non-MACEs group showed significant differences in patients with age >65 years (28 [50.0%] vs 319 [23.7%]), history of heart failure (16 [28.6%] vs 127 [9.4%]), history of ischemic stroke (14 [25.0%] vs 186 [13.8%]), history of cardiogenic shock (6 [10.71%] vs 16 [1.19%]), left ventricular ejection fraction <40% (8 [14.29%] vs 33 [2.46%]), and ALI <343.96 (44 [78.65%] vs 680 [50.60%]) (all p<0.001). The optimal cut-off value for ALI was 334.96. The area under the curve (AUC) of the 1-, 2-, 3-, and 5-year was 0.560, 0.577, 0.665, and 0.749, respectively. The survival rate was significantly lower in the low ALI group than in the high ALI group (log-rank p<0.001). Low ALI was an independent risk factor for the long-term prognosis of patients with ACS after PCI, univariate HR: 3.671, 95% CI: 1.938–6.953, p<0.001; multivariate HR: 3.009, 95% CI: 1.57–5.769, p=0.001. Conclusion ALI score less than 334.96 is an independent prognostic risk factor for patients with ACS undergoing PCI and may be a novel marker for clinical practice.

Association between advanced lung cancer inflammation index and in‐hospital mortality in ICU patients with community‐acquired pneumonia: A retrospective analysis of the MIMIC‐IV database

“…Recently, scholars have identified ALI < 334.96 to be an independent prognosis risk factor for acute coronary syndrome patients who underwent percutaneous coronary intervention. 16 This study suggested that ALI could serve as a novel biomarker in therapeutic settings. Despite the recognized importance of inflammation and nutrition in the context of CAP, research regarding the predictive value of ALI in CAP patients is lacking.…”

Predictive Value of the Advanced Lung Cancer Inflammation Index for the Postoperative Complications of Lung Resections in Patients with Bronchiectasis: A Retrospective Study Short Title : Study on the Correlation between the Advanced Lung Cancer Inflammation Index and Patients with Bronchiectasis

“…This index can simultaneously re ect the nutritional and in ammatory status of patients [14]. he correlation between a lower ALI and poorer prognosis has been established in various cancers and in ammatory diseases [15][16][17][18][19][20][21]. Nonetheless, research on the clinical signi cance of the ALI in bronchiectasis patients remains limited.…”

“…The Advanced Lung Cancer In ammation Index (ALI), which integrates BMI, the serum ALB concentration, and the neutrophil-to-lymphocyte ratio (NLR), was initially developed by Jafri et al to evaluate the prognosis of patients with metastatic non-small cell lung cancer (NSCLC) [14]. Subsequent studies have demonstrated that the ALI is effective in predicting the outcomes of various cancers, including hepatocellular carcinoma, esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, and even benign conditions such as hypertension, acute coronary syndrome, and diabetes mellitus [15][16][17][18][19][20][21]. Additionally, the ALI has been utilized as a predictor of postoperative complications in colon cancer patients [22].…”